Adaptimmune Therapeutics Plc (ADAPY)
0.037
0.00 (0.00%)
USD |
OTCM |
Oct 02, 16:00
Adaptimmune Therapeutics Profit Margin (Quarterly)
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2025 | -221.8% |
| March 31, 2025 | -653.2% |
| December 31, 2024 | -2.30K% |
| September 30, 2024 | -43.07% |
| June 30, 2024 | 54.22% |
| March 31, 2024 | -854.2% |
| December 31, 2023 | -20.74K% |
| September 30, 2023 | -623.1% |
| June 30, 2023 | -416.9% |
| March 31, 2023 | 2.18% |
| December 31, 2022 | -265.2% |
| September 30, 2022 | -591.1% |
| June 30, 2022 | -803.9% |
| March 31, 2022 | -1.41K% |
| December 31, 2021 | -2.74K% |
| September 30, 2021 | -3.52K% |
| June 30, 2021 | -1.26K% |
| March 31, 2021 | -8.70K% |
| December 31, 2020 | -2.44K% |
| Date | Value |
|---|---|
| September 30, 2020 | -2.97K% |
| June 30, 2020 | -5.95K% |
| March 31, 2020 | -3.70K% |
| December 31, 2019 | -4.03K% |
| September 30, 2019 | -16.58K% |
| June 30, 2019 | -26.17K% |
| March 31, 2019 | |
| December 31, 2018 | -2.45K% |
| September 30, 2018 | 12.85% |
| June 30, 2018 | -485.1% |
| March 31, 2018 | -257.2% |
| December 31, 2017 | -638.5% |
| September 30, 2017 | -3.23% |
| June 30, 2017 | -574.1% |
| March 31, 2017 | -762.4% |
| December 31, 2016 | -180.6% |
| September 30, 2016 | -765.5% |
| June 30, 2016 | -6.74K% |
| March 31, 2016 | -533.8% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Oxford Biomedica Plc | -- |
| Kiniksa Pharmaceuticals International Plc | 10.44% |
| Autolus Therapeutics Plc | -85.60% |
| Bicycle Therapeutics Plc | -8.00K% |
| Scancell Holdings Plc | -- |